Oncolytics Biotech
ONCY
20 hedge funds and large institutions have $3.22M invested in Oncolytics Biotech in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.91% more ownership
Funds ownership: 0% → 3.91% (+3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.01M |
| 2 |
Morgan Stanley
New York
|
+$289K |
| 3 |
Comerica Bank
Dallas,
Texas
|
+$95.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$54.8K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$49.2K |
Top Sellers
ONCY Hedge Fund Activity: Q2 2018 in Review
20 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2018, worth a combined $3.22M.
Buyers outnumbered sellers: 20 funds opened new ONCY positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.01M.
- 20 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $3.22M of Oncolytics Biotech stock for Q2 2018.
- 20 funds opened new Oncolytics Biotech positions in Q2 2018 and 0 closed out, a net change of +20 holders.
- The largest Oncolytics Biotech buyer in Q2 2018 was Millennium Management, an estimated $3.01M added.
Based on aggregated 13F filings for Q2 2018.